Brand-name vs compounded GLP-1 in 2026: what FDA rules mean for you
If you can access and afford a brand-name GLP-1 such as Wegovy (semaglutide) or Zepbound (tirzepatide), it is the option with the strongest safety assurance, because FDA has reviewed and approved those exact products for chronic weight management. Compounded semaglutide and tirzepatide are not FDA-approved, and since FDA declared the national shortages of both drugs resolved, the broad leeway compounders had during the shortage is over. Compounding is still legal in narrower situations, mainly when a state-licensed 503A pharmacy prepares a drug for one patient whose prescriber documents a real clinical need that the approved product cannot meet.
That is the short answer. The rest of this post explains the rules in plain English, so you can ask any clinic, including ours, the right questions before your first injection.
What compounding is, and why 503A vs 503B matters
Compounding means a pharmacist combines, mixes or alters ingredients to make a medication tailored to a patient. It exists for good reasons: someone allergic to a dye or preservative in a commercial product, or a patient who needs a dose or form that is not manufactured.
Federal law sorts compounders into two groups, named after sections of the Food, Drug, and Cosmetic Act:
- 503A pharmacies are state-licensed pharmacies that compound based on individual prescriptions for specific patients. State boards of pharmacy are their main overseers.
- 503B outsourcing facilities register with FDA, are inspected by FDA, and must meet current good manufacturing practice standards. They can make larger batches, including for office use without a patient-specific prescription.
The key point is the one most patients miss: neither type makes an FDA-approved drug. As FDA explains in its page on concerns with unapproved GLP-1 drugs used for weight loss, compounded drugs are not reviewed by the agency for safety, effectiveness or quality before they reach you. For a deeper background on how compounding pharmacies differ from traditional ones, see our post on compound vs traditional pharmacies.
| Brand-name (Wegovy, Zepbound) | 503A compounded | 503B compounded | |
|---|---|---|---|
| FDA-approved product | Yes | No | No |
| Main regulator | FDA (manufacturer) | State board of pharmacy | FDA registration and inspection |
| Manufacturing standard | Current good manufacturing practice | State pharmacy standards | Current good manufacturing practice |
| Needs an individual prescription | Yes | Yes | Not always |
| Typical format | Prefilled pen with set doses | Often a vial and syringe | Often a vial and syringe |
The brand-name versions approved for weight loss are indicated for adults with obesity, or adults who are overweight with at least one weight-related health condition, used alongside diet and physical activity. Ozempic and Mounjaro contain the same molecules but are approved for type 2 diabetes, not weight management. Both weight-loss labels also carry a boxed warning about thyroid C-cell tumors seen in rodents, and they are not for people with a personal or family history of medullary thyroid carcinoma or MEN 2. That is one reason a real medical evaluation comes before any prescription.
The shortage timeline: why compounded GLP-1s boomed, then got squeezed
Compounders are normally not allowed to make copies of commercially available approved drugs. One major exception applies when a drug is on FDA's shortage list. Starting in 2022, demand for semaglutide and tirzepatide outran supply, both drugs landed on that list, and compounded versions spread quickly through telehealth.
Then supply caught up. According to FDA's statement clarifying policies for compounders as national GLP-1 supply stabilized, the agency determined the tirzepatide shortage was resolved in late 2024 and the semaglutide shortage was resolved in February 2025. FDA gave compounders transition periods to wind down, with 503A pharmacies and 503B facilities on slightly different schedules, and said that after those windows closed it would no longer hold back enforcement against compounders making copies.
| Stage | What it meant for you |
|---|---|
| Shortages listed (2022) | Compounders could legally make copies of semaglutide and tirzepatide |
| Tirzepatide shortage resolved (late 2024) | Countdown began for compounders to stop routine copies of tirzepatide |
| Semaglutide shortage resolved (February 2025) | Same countdown began for semaglutide |
| Transition periods ended (by spring 2025) | Routine copying of either drug no longer protected by the shortage exception |
| 503B bulks list proposal | FDA moved to close another route for outsourcing facilities |
FDA's proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list
Outsourcing facilities can compound from raw bulk ingredients in two main situations: the drug is on the shortage list, or the bulk substance is on what FDA calls the 503B bulks list, which covers ingredients FDA finds there is a clinical need to compound. With the shortages over, the bulks list became the remaining question for these three GLP-1s.
FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. If finalized, outsourcing facilities could not compound these drugs from bulk ingredients unless a shortage returned. A proposal is not a final rule, so check FDA's page for current status. It also concerns 503B facilities specifically; 503A pharmacies follow a separate set of conditions, covered below. The direction is clear, though: FDA does not see a general clinical need for compounded versions when approved products are available.
Why FDA is concerned: dosing errors, salt forms and imported ingredients
FDA's concerns page on unapproved GLP-1 drugs lays out several problems in plain terms.
Dosing errors. Brand-name pens deliver preset doses. Many compounded products come in vials that you draw up with a syringe, sometimes at concentrations that differ from pharmacy to pharmacy. FDA has received reports of adverse events tied to dosing mistakes, including people measuring the wrong amount or confusing units with milliliters, and some cases required medical care.
Unapproved salt forms. Some compounders have used semaglutide sodium or semaglutide acetate. These are different active ingredients from the semaglutide in approved products, and FDA has said it is not aware of a lawful basis for compounding with them.
Illegal and imported ingredients. FDA has warned about products sold online without a prescription, products labeled "for research use only," and active ingredients from unverified overseas sources. FDA has also used an import alert with a "green list" approach intended to keep GLP-1 ingredients from unvetted manufacturers out of the US supply.
None of this means every compounded product is unsafe. It means the burden of checking quality shifts from FDA to you and your prescriber.
What is still allowed: patient-specific clinical need under 503A
Federal law still lets a 503A pharmacy compound a drug for an individual patient when the prescriber determines there is a change that makes a clinically significant difference for that patient, for example removing an inactive ingredient the patient is allergic to. What a 503A pharmacy cannot do is regularly make products that are essentially copies of a commercially available approved drug. FDA's compounder policy statement is the best place to read the agency's current framing, and state pharmacy laws add their own requirements.
In practice, price alone is not a clinical difference. If a clinic describes its compounded product as simply "cheaper Wegovy," that should prompt more questions, not fewer.
How to start a GLP-1 program, and questions to ask any clinic
A responsible medical weight loss program follows the same arc whether the medication is brand-name or compounded: a medical history and evaluation, a check of whether you meet the approved criteria, baseline labs, a prescription, a gradual dose increase (titration), and ongoing monitoring for side effects and progress.
At BioCure Health, that looks like a five-minute online intake, a $199 physician video consultation that can be credited back with a membership, and a required blood panel before semaglutide or tirzepatide is prescribed. Both are given as weekly injections with escalating doses and then a maintenance phase, with physician supervision, regular check-ins and support after you reach your goal. Details are on our medical weight loss page, and you can meet the physicians on our team page. BioCure's homepage advertises custom compounded protocols, and the clinic works with licensed compounding pharmacy partners. Before you start, you should know in writing whether your own GLP-1 prescription is brand-name or compounded and which pharmacy fills it. Hold us to the same checklist below.
| Question to ask | Why it matters | A good answer sounds like |
|---|---|---|
| Is this an FDA-approved product or a compounded one? | Only approved products have FDA review | A direct yes or no, plus the product name |
| Which pharmacy fills it, and is it 503A or 503B? | Determines who inspects it and what rules apply | A named, licensed pharmacy you can look up |
| What form of the active ingredient is it? | FDA has flagged salt forms like semaglutide sodium | The same base molecule as the approved drug |
| If compounded, what is my clinical reason? | 503A compounding requires a patient-specific need | A documented reason tied to your health |
| How is my dose measured and delivered? | Vial and syringe dosing is where errors happen | Clear instructions in milligrams, with a demonstration |
| Who monitors me, and how often? | Side effects and titration need oversight | A named clinician and scheduled check-ins |
Frequently asked questions
Is compounded semaglutide still legal in 2026?
It is legal only in narrower circumstances than during the shortage. A state-licensed 503A pharmacy can compound for an individual patient when a prescriber documents a clinically significant need, but routine copies of approved products are no longer protected now that FDA has declared the shortage resolved.
Is compounded tirzepatide the same as Zepbound?
No. Zepbound is an FDA-approved product made under federal manufacturing standards; compounded tirzepatide is not reviewed by FDA for safety, effectiveness or quality. Concentration, ingredients and delivery format can also differ between pharmacies.
What is the difference between a 503A and a 503B pharmacy?
A 503A pharmacy is state-licensed and compounds for individual prescriptions, with the state board of pharmacy as its main regulator. A 503B outsourcing facility registers with FDA, is inspected by FDA and must follow current good manufacturing practice. Neither produces FDA-approved drugs.
Why is FDA worried about compounded GLP-1 injections?
FDA has cited dosing errors with vial and syringe products, use of salt forms such as semaglutide sodium and acetate, and ingredients from unverified sources sold online or imported. Some dosing errors have led to adverse events that needed medical care.
How do I start a medical weight loss program with a GLP-1?
Start with a clinician who reviews your history, checks whether you meet the approved criteria and orders baseline labs. Expect a gradual dose increase and regular follow-up. Ask whether your prescription is brand-name or compounded before you begin.
Does BioCure prescribe brand-name or compounded GLP-1s?
BioCure advertises custom compounded protocols and works with licensed compounding pharmacy partners. Your physician should tell you whether your specific prescription is brand-name or compounded, which pharmacy fills it and why, before you start.
The right GLP-1 is not the cheapest or the most convenient one. It is the one you understand: what it is, where it comes from, and who is watching your progress. Weight loss done well is intentional, not accidental.
Let BioCure Health lead you in the right direction. Call or text us to schedule an introductory call at 754-206-0838. Your future self will thank you.